Medical uses of scuPA/suPAR complex

Details Medical uses of scuPA/suPAR complex Medical uses of scuPA/suPAR complex

2005-06-28

2005-06-28

Harris, Alana M. (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving blood clotting factor

C435S004000, C435S007100, C435S007210, C435S007910, C435S007920, C436S086000, C436S536000, C436S512000, C436S513000, C530S350000, C530S380000, C530S300000, C530S385000, C530S386000, C530S387100, C514S001000, C514S002600, C514S014800

Reexamination Certificate

active

06911316

ABSTRACT:
Methods of using a complex (scuPA/suPAR) which has thrombolytic activity under physiological conditions and in the presence of IgG, or of at least one IgG-derived peptide, which complex comprises a single chain urokinase type plasminogen activator (scuPA) and a soluble urokinase plasminogen activator receptor (suPAR), for the treatment and/or prevention of thromboembolic disorders associated with the formation of fibrin clots are disclosed.

REFERENCES:
patent: 5455044 (1995-10-01), Kim et al.
patent: 5558852 (1996-09-01), Bigner et al.
Harlow and Lane. Antibodies, A Laboratory Manual, Chapter 59:96-99, 1988.
Lindahl, T.L. et al., “The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator,”Biochem. J. 265(1):109-113 (1990).
Ploug, M. et al., “Ligand Interaction between Urokinase-Type Plasminogen Activator and Its Receptor Probed with 8-Anilino-1-naphthalenesulfonate. Evidence for a Hydrophobic Binding Site Exposed Only on the Intact Receptor,”Biochemistry, 33:8991-8997 (1994).
Pannell; R. et al., “Activation of Plasminogen by Single-Chain Urokinase or by Two-Chain Urokinase—A Demonstration That Single-Chain Urokinase Has a Low Catalytic Activity (Pro-Urokinase),”Blood, 69(1):22-26 (1987).
Collen, D., “On the Regulation and Control of Fibrinolysis,”Thrombosis and Haemostasis, 43(2):77-89 (1980).
Lijnen, H.R. et al., “The Mechanism of Plasminogen Activation and Fibrin Dissolution by Single Chain Urokinase-Type Plasminogen Activator in a Plasma Milieu In Vitro,”Blood, 73(7):1864-1872 (1989).
Wang, J. et al., “Plasminogen activation by pro-urokinase in complex with its receptor Dependence on a tripeptide (Spectrozyme plasmin),”Eur. J. Biochem. 247(1):256-261 (1997).
Behrendt, N. et al., “Reply to comment on ‘Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system’ (A.A-R. Higazi),”FEBS Letters 402:293-294 (1997).
Deutsch, D.G. et al., “Plasminogen: Purification from Human Plasma by Affinity Chromatography,”Science, 170(3962):1095-1096 (1970).
Kasai, S. et al., “Primary Structure of Single-chain Pro-urokinase,”J. Biol. Chem., 260(22):12382-12389 (1985).
Ellis, V. et al., “Inhibition of Receptor-bound Urokinase by Plasminogen-activator Inhibitors,”J. Biol. Chem., 265(17):9904-9908 (1990).
Ellis, V. et al., “Plasminogen Activation by Receptor-bound Urokinase,”J. Biol. Chem., 266(19):12752-12758 (1991).
Schwartz, B.S., “Differential Inhibition of Soluble and Cell Surface Receptor-bound Single chain Urokinase by Plasminogen Activator Inhibitor Type 2,”J. Biol. Chem., 269(11):8319-8323 (1994).
Higazi, A.A. et al., “Identification of an Inhibitor of Tissue-type Plasminogen Activator-mediated Fibrinolysis in Human Neutrophils,”J. Biol. Chem. 270(16):9472-9477 (1995).
Del Villar, K. et al., “Amino Acid Substitutions That Convert the Protein Substrate Specificity of Farnesyltransferase to That of Geranylgeranyltransferase Type I,”J. Biol. Chem., 272(1):680-687 (1997).
Zhang, L. et al., “Regulation of Single Chain Urokinase Binding, Internalization, and Degradation by a Plasminogen Activator Inhibitor 1-Derived Peptide,”J. Biol. Chem. 272(43):27053-27057 (1997).
Behrendt, N. et al., “Domain Interplay in the Urokinase Receptor,”J. Biol. Chem., 271(37):22885-22894 (1996).
Ellis, V., “Functional Analysis of the Cellular Receptor for Urokinase in Plasminogen Activation,”J. Biol. Chem., 271(25):14779-14784 (1996). JBC OnlineBio. Mol.pp. 1-13.
Higazi, A.A. et al., “Regulation of fibrinolysis by non-esterified fatty acids,”Biochem J., 300:251-255 (1994).
Higazi, A.A. et al., “Regulation of Single Chain Urokinase by Small Peptides,”Thromb. Res. 84(4):243-252 (1996).
Higazi, A.A. et al., “Enhancement of the Enzymatic Activity of Single-chain Urokinase Plasminogen Activator by Soluble Urokinase Receptor,”J. Biol. Chem. 270(29):17375-17380 (1995).
Higazi, A.A. et al., “Unesterified Long Chain Fatty Acids Inhibit the Binding of Single Chain Urokinase to the Urokinase Receptor,”Biochemistry, 35(21):6884-6890 (1996).
Higazi, A.A. et al., “Interaction of Single-Chain Urokinase With Its Receptor Induces the Appearance and Disappearance of Binding Epitopes Within the Resultant Complex for Other Cell Surface Proteins.”Blood, 88(2):542-551 (1996).
Higazi, A.A. et al., “Single Chain Urokinase-Type Plasminogen Activator Bound To Its Receptor Is Relatively Resistant To Plasminogen Activator Inhibitor Type 1,”Blood, 87(9):3545-3549 (1996).
Higazi, A.A. et al., “Lysis of Plasma Clots by Urokinase-Soluble Urokinase Receptor Complexes,”Blood, 92(6):2075-2083(1998).
Higazi, A.A. et al., “Soluble Human Urokinase Receptor Is Composed of Two Active Units,”J. Biol. Chem., 272(8):5348-5353 (1997).
Higazi, A.A., “Commentary on: ‘Effect of purified soluble urokinase receptor on the plasminogen prourokinase activation system’ by N. Behrendt and K. Dano,FEBS Letters, 393(1996) 31-36”,FEBS Letters 402:291-292 (1997).
Behrendt, N., et al., “The Structure and Function of the Urokinase Receptor, a Membrane Protein Governing Plasminogen Activation on the Cell Surface,”Biol. Chem. Hoppe-Seyler 376:269-279 (1995).

Affiliated with

Also associated with

Rating

Medical uses of scuPA/suPAR complex does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medical uses of scuPA/suPAR complex, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medical uses of scuPA/suPAR complex will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3475955